Please assess the completion status of the following clinical trial:

Trial Title: Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Histologically Verified Adenocarcinoma Prostatae~3. Diagnostic and / or histologically verified lymph node metastases~4. ECOG Performance Status ≤2~5. Primary anti-androgen treatment started~6. Adequate haematological, renal and hepatic function:~   1. Neutrophil granulocytes ≥ 1.5 x 109 / l~  2. Platelet counts ≥ 100 x 109 / l~  3. hemoglobin ≥ 5.6 mmol / l~  4. Serum creatinine ≤ 1.5 times upper normal limit~  5. AST or ALAT ≤ 2.5 times upper normal limit~  6. serum bilirubin ≤ 1.5 times upper normal limit~  7. Alkaline phosphatase ≤ 2.5 times upper normal limit~  8. INR \<1.5 / PP \<40~Exclusion Criteria:~1. Verified bone or visceral metastases~2. Serious allergy or previous anaphylactic reactions~3. Known hypersensitivity to any of the active substances or to any of the excipients.~4. Other malignant disease within the last three years, rendering planocellular and basocellular skin carcinoma~5. Known infection with HIV, hepatitis B and C virus, regardless of whether the infection is kept calm with medical treatment~6. Severe medical disorder, severe asthma, severe COPD, poorly regulated cardiovascular disease or diabetes~7. Active autoimmune disease, e.g. autoimmune neutropenia / thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, goodpasture syndrome, Addison's disease, Hashimoto's thyroiditis, active grave disease, morbus chrohn or ulcerative colitis~8. Major gastrointestinal surgical procedures within the last 3 months~9. Previous treatment with other cancer vaccine~10. Concomitant immunosuppressive treatment including prednisolone and methotrexate~11. Ongoing anticoagulant treatment (treatment with acetylsalicylic acid and clopidogrel is allowed)~12. Psychiatric disease which, according to the investigator's discretion, may affect compliance~13. Co-administration with other experimental drugs.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: IM followed by IP (Type: EXPERIMENTAL): Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
- Arm B: IP followed by IM (Type: EXPERIMENTAL): Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.

Based on this trial design, predict the completion outcome and termination type (if applicable).